269 related articles for article (PubMed ID: 29959362)
21. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L
Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas.
Zhan P; Shen XK; Qian Q; Zhu JP; Zhang Y; Xie HY; Xu CH; Hao KK; Hu W; Xia N; Lu GJ; Yu LK
Med Oncol; 2012 Jun; 29(2):648-55. PubMed ID: 21519871
[TBL] [Abstract][Full Text] [Related]
23. High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients.
Yu LM; Zhu YS; Xu CZ; Zhou LL; Xue ZX; Cai ZZ
Clin Transl Oncol; 2019 Jul; 21(7):924-932. PubMed ID: 30565085
[TBL] [Abstract][Full Text] [Related]
24. LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing
Peng T; Lin S; Meng Y; Gao P; Wu P; Zhi W; Ding W; Cao C; Wu P
Cell Cycle; 2022 Sep; 21(17):1827-1841. PubMed ID: 35509127
[TBL] [Abstract][Full Text] [Related]
25. Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2.
Kim HS; Lee YS; Dong SM; Kim HJ; Lee DE; Kang HW; Kim MJ; Park JS
Oncol Res; 2024; 32(4):615-624. PubMed ID: 38560567
[TBL] [Abstract][Full Text] [Related]
26. 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma.
Xu J; Li D; Li X; Liu Z; Li T; Jiang P; He Q; Tian F; Gao Y; Wang D; Wang S
Dig Liver Dis; 2014 Aug; 46(8):750-7. PubMed ID: 24794791
[TBL] [Abstract][Full Text] [Related]
27. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL
Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405
[TBL] [Abstract][Full Text] [Related]
28. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
29. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.
Peng L; Ran YL; Hu H; Yu L; Liu Q; Zhou Z; Sun YM; Sun LC; Pan J; Sun LX; Zhao P; Yang ZH
Carcinogenesis; 2009 Oct; 30(10):1660-9. PubMed ID: 19625348
[TBL] [Abstract][Full Text] [Related]
30. Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is critically required for differentiation.
Iftikhar M; Hurtado P; Bais MV; Wigner N; Stephens DN; Gerstenfeld LC; Trackman PC
J Biol Chem; 2011 Jan; 286(2):909-18. PubMed ID: 21071451
[TBL] [Abstract][Full Text] [Related]
31. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
Peng DH; Ungewiss C; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Uraoka N; Mino B; Behrens C; Wistuba II; Han RI; Wanna CA; Fahrenholtz M; Grande-Allen KJ; Creighton CJ; Gibbons DL
Oncogene; 2017 Apr; 36(14):1925-1938. PubMed ID: 27694892
[TBL] [Abstract][Full Text] [Related]
32. Prognostic utility and clinical significance of lysyl oxidase-like 2 protein expression in digestive system cancers.
Zhang Y; Liu W; Xu J
J Cell Physiol; 2019 Nov; 234(11):20713-20720. PubMed ID: 30997684
[TBL] [Abstract][Full Text] [Related]
33. Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer.
Zhan P; Lv XJ; Ji YN; Xie H; Yu LK
Clin Respir J; 2018 Feb; 12(2):712-720. PubMed ID: 27860390
[TBL] [Abstract][Full Text] [Related]
34. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.
Brekhman V; Lugassie J; Zaffryar-Eilot S; Sabo E; Kessler O; Smith V; Golding H; Neufeld G
FASEB J; 2011 Jan; 25(1):55-65. PubMed ID: 20802105
[TBL] [Abstract][Full Text] [Related]
35. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma.
Lv GQ; Zou HY; Liao LD; Cao HH; Zeng FM; Wu BL; Xie JJ; Fang WK; Xu LY; Li EM
Biochem Cell Biol; 2014 Oct; 92(5):379-89. PubMed ID: 25275797
[TBL] [Abstract][Full Text] [Related]
36. Reciprocal regulation of LOX and LOXL2 expression during cell adhesion and terminal differentiation in epidermal keratinocytes.
Fujimoto E; Tajima S
J Dermatol Sci; 2009 Aug; 55(2):91-8. PubMed ID: 19394199
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of lysyl oxidase and lysyl oxidase-like protein 2 suppressed the migration and invasion of trophoblasts by activating the TGF-β/collagen pathway in preeclampsia.
Xu XH; Jia Y; Zhou X; Xie D; Huang X; Jia L; Zhou Q; Zheng Q; Zhou X; Wang K; Jin LP
Exp Mol Med; 2019 Feb; 51(2):1-12. PubMed ID: 30804321
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3.
Hu H; Wang Y; Ding X; He Y; Lu Z; Wu P; Tian L; Yuan H; Liu D; Shi G; Xia T; Yin J; Cai B; Miao Y; Jiang K
Mol Cancer; 2018 Jan; 17(1):18. PubMed ID: 29386037
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-494 acts as a tumor suppressor in pancreatic cancer, inhibiting epithelial-mesenchymal transition, migration and invasion by binding to SDC1.
Yang Y; Tao X; Li CB; Wang CM
Int J Oncol; 2018 Sep; 53(3):1204-1214. PubMed ID: 29956739
[TBL] [Abstract][Full Text] [Related]
40. Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization.
Canesin G; Cuevas EP; Santos V; López-Menéndez C; Moreno-Bueno G; Huang Y; Csiszar K; Portillo F; Peinado H; Lyden D; Cano A
Oncogene; 2015 Feb; 34(8):951-64. PubMed ID: 24632622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
